ZAI LAB LIMITED Selling, General and Administrative Expense
ZAI LAB LIMITED (ZLAB) reported Selling, General and Administrative Expense of $72.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- ZAI LAB LIMITED selling, general and administrative expense for the quarter ending 2026-06-30 was $72.87M, a 2.58% increase year-over-year.
- ZAI LAB LIMITED selling, general and administrative expense for the quarter ending 2026-03-31 was $65.07M, a 2.60% increase year-over-year.
- ZAI LAB LIMITED selling, general and administrative expense for the quarter ending 2025-12-31 was $73.04M, a 11.59% decline year-over-year.
- ZAI LAB LIMITED selling, general and administrative expense for the quarter ending 2025-09-30 was $70.11M, a 4.29% increase year-over-year.
- ZAI LAB LIMITED selling, general and administrative expense for fiscal 2025 was $277.61M, a 7.08% decline from fiscal 2024.
- ZAI LAB LIMITED selling, general and administrative expense for fiscal 2024 was $298.74M, a 6.08% increase from fiscal 2023.
- ZAI LAB LIMITED selling, general and administrative expense for fiscal 2023 was $281.61M, a 8.74% increase from fiscal 2022.
- ZAI LAB LIMITED selling, general and administrative expense for fiscal 2022 was $258.97M, a 18.34% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $72.87M 10-Q · filed 2026-08-06 | $137.94M 10-Q · filed 2026-08-06 | $210.98M derived: sum of 3 quarters · filed 2026-08-06 | $281.09M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $65.07M 10-Q · filed 2026-05-07 | $138.11M derived: sum of 2 quarters · filed 2026-05-07 | $208.22M derived: sum of 3 quarters · filed 2026-05-07 | $279.25M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $73.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $143.15M derived: sum of 2 quarters · filed 2026-02-26 | $214.18M derived: sum of 3 quarters · filed 2026-08-06 | $277.61M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $70.11M 10-Q · filed 2025-11-06 | $141.14M derived: sum of 2 quarters · filed 2026-08-06 | $204.57M 10-Q · filed 2025-11-06 | $287.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $71.04M 10-Q · filed 2026-08-06 | $134.46M 10-Q · filed 2026-08-06 | $217.08M derived: sum of 3 quarters · filed 2026-08-06 | $284.30M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $63.42M 10-Q · filed 2026-05-07 | $146.04M derived: sum of 2 quarters · filed 2026-05-07 | $213.26M derived: sum of 3 quarters · filed 2026-05-07 | $292.97M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $82.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $149.84M derived: sum of 2 quarters · filed 2026-02-26 | $229.55M derived: sum of 3 quarters · filed 2026-02-26 | $298.74M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $67.22M 10-Q · filed 2025-11-06 | $146.93M derived: sum of 2 quarters · filed 2025-11-06 | $216.12M 10-Q · filed 2025-11-06 | $298.75M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $79.71M 10-Q · filed 2025-08-07 | $148.90M 10-Q · filed 2025-08-07 | $231.53M derived: sum of 3 quarters · filed 2026-02-26 | $300.08M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $69.19M 10-Q · filed 2025-05-08 | $151.82M derived: sum of 2 quarters · filed 2026-02-26 | $220.37M derived: sum of 3 quarters · filed 2026-02-26 | $288.29M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $82.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $151.18M derived: sum of 2 quarters · filed 2026-02-26 | $219.10M derived: sum of 3 quarters · filed 2026-02-26 | $281.61M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $68.55M 10-Q · filed 2024-11-12 | $136.47M derived: sum of 2 quarters · filed 2024-11-12 | $198.98M 10-Q · filed 2024-11-12 | $271.01M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $67.92M 10-Q · filed 2024-08-06 | $130.43M 10-Q · filed 2024-08-06 | $202.45M derived: sum of 3 quarters · filed 2025-02-27 | $269.01M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $62.51M 10-Q · filed 2024-05-08 | $134.53M derived: sum of 2 quarters · filed 2025-02-27 | $201.09M derived: sum of 3 quarters · filed 2025-02-27 | $264.49M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $72.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $138.58M derived: sum of 2 quarters · filed 2025-02-27 | $201.98M derived: sum of 3 quarters · filed 2025-02-27 | $258.97M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $66.56M 10-Q · filed 2023-11-07 | $129.96M derived: sum of 2 quarters · filed 2023-11-07 | $186.95M 10-Q · filed 2023-11-07 | $256.52M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $63.40M 10-Q · filed 2023-08-07 | $120.39M 10-Q · filed 2023-08-07 | $189.97M derived: sum of 3 quarters · filed 2024-02-27 | $248.97M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $56.99M 10-Q · filed 2023-05-09 | $126.57M derived: sum of 2 quarters · filed 2024-02-27 | $185.57M derived: sum of 3 quarters · filed 2024-02-27 | $239.98M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $69.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $128.58M derived: sum of 2 quarters · filed 2024-02-27 | $182.99M derived: sum of 3 quarters · filed 2024-02-27 | $218.83M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $59.00M 10-Q · filed 2022-11-09 | $113.42M derived: sum of 2 quarters · filed 2022-11-09 | $149.25M 10-Q · filed 2022-11-09 | $190.22M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $54.41M 10-Q · filed 2022-08-09 | $90.25M 10-Q · filed 2022-08-09 | $131.22M derived: sum of 3 quarters · filed 2023-03-01 | $159.09M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $35.84M 10-Q · filed 2022-05-10 | $76.80M derived: sum of 2 quarters · filed 2023-03-01 | $104.68M derived: sum of 3 quarters · filed 2023-03-01 | $128.44M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $40.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $68.84M derived: sum of 2 quarters · filed 2023-03-01 | $92.60M derived: sum of 3 quarters · filed 2023-03-01 | $111.31M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $27.87M 10-Q · filed 2021-11-09 | $51.63M derived: sum of 2 quarters · filed 2021-11-09 | $70.35M 10-Q · filed 2021-11-09 | $93.37M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $23.76M 10-Q · filed 2021-08-09 | $42.47M 10-Q · filed 2021-08-09 | $65.50M derived: sum of 3 quarters · filed 2022-03-01 | $83.19M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $18.71M 10-Q · filed 2021-05-10 | $41.74M derived: sum of 2 quarters · filed 2022-03-01 | $59.44M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $23.02M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $40.72M derived: sum of 2 quarters · filed 2022-03-01 | $70.21M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $17.70M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $47.19M 6-K · filed 2020-01-21 | |||
| 2019-06-30 | $29.49M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $10.98M derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $21.58M 10-K · filed 2021-03-01 | $21.58M 20-F · filed 2019-03-29 | ||
| 2018-09-30 | $10.60M 6-K · filed 2020-01-21 | ||||
| 2017-12-31 | $12.05M 20-F · filed 2020-04-29 | $12.05M 20-F · filed 2019-03-29 | |||
| 2016-12-31 | $6.38M 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |